[HTML][HTML] Lipoprotein (a): structure, pathophysiology and clinical implications

RC Maranhão, PO Carvalho, CC Strunz… - Arquivos brasileiros de …, 2014 - SciELO Brasil
The chemical structure of lipoprotein (a) is similar to that of LDL, from which it differs due to
the presence of apolipoprotein (a) bound to apo B100 via one disulfide bridge. Lipoprotein …

Lipoprotein (a) the insurgent: a new insight into the structure, function, metabolism, pathogenicity, and medications affecting lipoprotein (a) molecule

MM Jawi, J Frohlich, SY Chan - Journal of lipids, 2020 - Wiley Online Library
Lipoprotein (a)[Lp (a)], aka “Lp little a”, was discovered in the 1960s in the lab of the
Norwegian physician Kåre Berg. Since then, we have greatly improved our knowledge of …

Effect of extended-release niacin on plasma lipoprotein (a) levels: a systematic review and meta-analysis of randomized placebo-controlled trials

A Sahebkar, Ž Reiner, LE Simental-Mendia, G Ferretti… - Metabolism, 2016 - Elsevier
Abstract Aim Lipoprotein (a)(Lp (a)) is a proatherogenic and prothrombotic lipoprotein. Our
aim was to quantify the extended-release nicotinic acid Lp (a) reducing effect with a meta …

Lipoprotein (a) in atherosclerosis: from pathophysiology to clinical relevance and treatment options

A Rehberger Likozar, M Zavrtanik… - Annals of medicine, 2020 - Taylor & Francis
Abstract Lipoprotein (a)(Lp (a)) was discovered more than 50 years ago, and a decade later,
it was recognized as a risk factor for coronary artery disease. However, it has gained …

Consumption of a defined, plant‐based diet reduces lipoprotein (a), inflammation, and other atherogenic lipoproteins and particles within 4 weeks

RS Najjar, CE Moore, BD Montgomery - Clinical cardiology, 2018 - Wiley Online Library
Background Lipoprotein (a)[Lp (a)] is a highly atherogenic lipoprotein and is minimally
effected by lifestyle changes. While some drugs can reduce Lp (a), diet has not consistently …

[HTML][HTML] PCSK9 in haemostasis and thrombosis: possible pleiotropic effects of PCSK9 inhibitors in cardiovascular prevention

F Paciullo, S Momi, P Gresele - Thrombosis and Haemostasis, 2019 - thieme-connect.com
Since increased cholesterol levels are crucial in determining the development of atheroma,
their reduction represents a mainstay in primary and secondary cardiovascular prevention …

Lipoprotein (a) in cardiovascular diseases

M Malaguarnera, M Vacante, C Russo… - BioMed research …, 2013 - Wiley Online Library
Lipoprotein (a)(Lp (a)) is an LDL‐like molecule consisting of an apolipoprotein B‐100 (apo
(B‐100)) particle attached by a disulphide bridge to apo (a). Many observations have …

[HTML][HTML] Lipoproteínas: metabolismo y lipoproteínas aterogénicas

C Carvajal - Medicina Legal de Costa Rica, 2014 - scielo.sa.cr
Los lípidos viajan en sangre en diferentes partículas conteniendo lípidos y proteínas
llamadas lipoproteínas. Hay cuatro clases de lipoproteínas en sangre: quilomicrones, VLDL …

[HTML][HTML] Lipoprotein (a) where do we stand? from the physiopathology to innovative terapy

G Iannuzzo, M Tripaldella, V Mallardo, M Morgillo… - Biomedicines, 2021 - mdpi.com
A number of epidemiologic studies have demonstrated a strong association between
increasing lipoprotein a [Lp (a)] and cardiovascular disease. This correlation was …

Apolipoprotein profiling as a personalized approach to the diagnosis and treatment of dyslipidaemia

L Renee Ruhaak, A van der Laarse… - Annals of clinical …, 2019 - journals.sagepub.com
An elevated low-density lipoprotein cholesterol concentration is a classical risk factor for
cardiovascular disease. This has led to pharmacotherapy in patients with atherosclerotic …